Kewaunee Scientific Corp

This advisory proposal asks shareholders to approve, on a non-binding basis, the Company’s executive compensation program as disclosed in the proxy statement, including the Compensation Overview and compensation tables. Management seeks shareholder approval to demonstrate support for its compensation philosophy—designed to attract and retain executives, align management with shareholder interests, and balance short-term and long-term incentives—while preserving flexibility in compensation design. The Company highlights that its program places a significant portion of pay at risk through annual cash incentives tied largely to EBITDA objectives and long-term RSUs with time-based and performance-based vesting tied to multi-year EBITDA targets. The proxy notes prior strong support for say-on-pay in 2025 and describes proactive stockholder engagement (meetings with holders representing ~38.5% of shares) during which no material objections to the compensation program were raised, a fact management cites to justify recommending a vote FOR. While the vote is non-binding, the Board and Compensation Committee will consider the outcome when evaluating compensation policies; a negative outcome would likely prompt additional engagement and potential design changes. From a governance perspective, the program’s use of both time- and performance-based equity, multi-year performance periods, and metrics tied to EBITDA indicate an emphasis on multi-year value creation rather than short-term stock movements, though reliance on EBITDA as the principal financial metric may raise concerns for investors who prefer metrics linked to cash flow or ROIC. The Company also discloses significant pay-for-performance mechanics (e.g., target, threshold, and maximum payouts and a high CEO target opportunity) and change-in-control protections, which investors may scrutinize when assessing alignment. Overall, the Board’s recommendation reflects confidence in the program’s alignment with shareholder interests, but the advisory nature of the vote and the detailed disclosures mean shareholders retain the ability to influence future compensation design through feedback or future votes.

This catch-all item authorizes that any other matters properly brought before the meeting may be considered and acted upon. It does not specify particular actions, and historically such items are procedural or incidental; if substantive proposals unrelated to the enumerated items are presented, they must meet SEC and Company rules for inclusion and disclosure. Proxies accompanying the proxy statement indicate that, absent specific instructions, proxies will be cast in accordance with the proxy holders’ judgment on such matters, giving management and designated proxy holders flexibility to vote on unforeseen items. From a governance standpoint, the presence of an “other business” item preserves the ability to address urgent or late-arising matters but provides limited advance transparency to shareholders about potential substance. If a significant shareholder proposal were to be presented at the meeting under this item, the Company would typically need to disclose the submission and engage with shareholders about the matter, and the board’s response would depend on the proposal’s nature and timing. Shareholders concerned about last-minute or unannounced matters should note the Company’s stockholder proposal submission deadlines and universal proxy rules described in the proxy statement, which constrain the ability to present certain proposals without prior notice. Because the item is inherently undefined, its practical impact is usually minimal; however, in rare cases it could be used to introduce materially important items, in which case investors should evaluate the board’s position and any supplemental disclosures closely.